Status:
COMPLETED
Monitoring and Preventing Hydroxychloroquine, Plaquenil, Toxicity.
Lead Sponsor:
Dr. S.S. Michel Clinic
Conditions:
Hydroxychloroquine Toxicity
Eligibility:
All Genders
25-85 years
Brief Summary
Oral Hydoxychloroquine is a very popular medication widely used by patients with rheumatoid arthritis, Systemic Lupus Erythematosus and other diseases. Ocular side effects of this medication are very ...
Detailed Description
The ocular side effects of Hydroxychloroquine has been known for long time. Due to the seriousness of these side effects all possible efforts were done to prevent them. Preventing these side effects w...
Eligibility Criteria
Inclusion
- all patients who need treatment with oral Hydroxychloroquine.
- \-
Exclusion
- patients who are not using oral Hydroxychloroquine.
- \-
Key Trial Info
Start Date :
January 7 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 10 2017
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT03316092
Start Date
January 7 2010
End Date
October 10 2017
Last Update
October 23 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr. S.S. Michel Clinic
Edmonton, Alberta, Canada, T5R5W9